Sharecare (SHCR)
(Delayed Data from NSDQ)
$1.37 USD
-0.01 (-0.72%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $1.37 0.00 (0.00%) 5:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SHCR 1.37 -0.01(-0.72%)
Will SHCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SHCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SHCR
Alignment Healthcare (ALHC) Reports Q2 Loss, Tops Revenue Estimates
Sharecare, Inc. (SHCR) Reports Q1 Loss, Misses Revenue Estimates
SHCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Sharecare, Inc. (SHCR) to Report a Decline in Earnings: What to Look Out for
Sharecare, Inc. (SHCR) Reports Q4 Loss, Lags Revenue Estimates
GoodRx Holdings, Inc. (GDRX) Matches Q4 Earnings Estimates
Other News for SHCR
SHCR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Sharecare to Boston Scientific
Key Takeaways From Sharecare Analyst Ratings
Sharecare price target raised by 43c at Morgan Stanley, here's why
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sharecare (SHCR), Amylyx Pharmaceuticals Inc (AMLX) and Biogen (BIIB)
Hold Rating on Sharecare Amid Private Acquisition and Market Challenges